Submitted for Publication: April 5, 2013; final revision received September 21, 2013; accepted October 10, 2013.
Published Online: January 23, 2014. doi:10.1001/jamaophthalmol.2013.7630.
Study concept and design: Hauswirth, Boye, Guy.
Acquisition of data: Koilkonda, Yu, Chou, Porciatti, Tse, Hauswirth, Chiodo, Neuringer, Renner.
Analysis and interpretation of data: Koilkonda, Chou, Feuer, Ruggeri, Porciatti, Hauswirth, Lewin, Neuringer, Renner, Guy.
Drafting of the manuscript: Koilkonda, Guy.
Critical revision of the manuscript for important intellectual content: Yu, Chou, Feuer, Ruggeri, Tse, Hauswirth, Chiodo, Boye, Lewin, Neuringer, Renner, Guy.
Statistical analysis: Koilkonda, Feuer.
Obtained funding: Guy.
Administrative, technical, or material support: Chou, Ruggeri, Porciatti, Tse, Hauswirth, Boye, Neuringer, Renner, Guy.
Study supervision: Chou, Neuringer, Guy.
Conflict of Interest Disclosures: Dr Hauswirth owns equity in AGTC, which makes AAV vectors. Dr Hauswirth and Mr Boye are listed as inventors on a patent that applies to the AAV technology used in this article. No other disclosures were reported.
Funding/Support: This study was supported by grants R24EY018600, R01EY01714, and R01EY012355 from the National Eye Institute (Dr Guy); grants P30EY014801 (Dr Porciatti) and P51OD011092 (ONPRC core grant) from the National Institutes of Health; and unrestricted grants to Bascom Palmer Eye Institute and the University of Florida from Research to Prevent Blindness.
Role of the Sponsors: The funding sources had no role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, and approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: Mabel Wilson edited the manuscript.